A Phase 2A, Open-label Dose Finding Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With BETA(b)-THALASSEMIA
Latest Information Update: 08 Mar 2024
At a glance
- Drugs Sotatercept (Primary)
- Indications Beta-thalassaemia
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 11 Apr 2023 Status changed from completed to discontinued.
- 18 Aug 2022 Status changed from active, no longer recruiting to completed.
- 05 May 2022 Planned End Date changed from 29 Apr 2022 to 29 Jun 2022.